Colchicine for secondary prevention of vascular events: a meta-analysis of trials
Marc-André d’Entremont(Hamilton General Hospital), Sanjit S. Jolly(University Health Network), Jan H. Cornel(Brigham and Women's Hospital), Aernoud T.L. Fiolet(University Medical Center Utrecht), Michiel H.F. Poorthuis(University Medical Center Utrecht), Gilles Montalescot(Sorbonne Université), Ian Buysschaert(University of Utah), Arend Mosterd(Werkgroep Cardiologische centra Nederland), Shirley Jansen(Harry Perkins Institute of Medical Research), Binita Shah(New York University), Martin Teraa(Maine Farmland Trust), Noel Chan(McMaster University), Domingo A. Pascual‐Figal(Centro de Investigación Biomédica en Red), Jamie Layland(Peninsula Health), Peter J. Kelly(University College Dublin), Sasko Kedev(Ss. Cyril and Methodius University in Skopje), John W. Eikelboom(King's College Hospital), Kevin E. Boczar(University of Ottawa), Yongjun Wang(Beijing Tian Tan Hospital), Pierre Amarenco(Population Health Research Institute), Alfredo E. Rodríguez, Jalina Jannink(Meander Medisch Centrum), Nathan Mewton(Hospices Civils de Lyon), Aimee van Zelm(University Medical Center Utrecht), Anthony Keech(Heidelberg University)
Cited by 43
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Autophagy regulates lipid metabolism
|Nature|2009|3.9k